Starling Oncology Inc (STLN)

NASD · Healthcare · Medical Care Facilities · USA

Starling Oncology Inc is a small cap company (market value between $300 million and $2 billion) in the Medical Care Facilities industry.

Starling Oncology Inc provides cancer care services across multiple markets in several states through physician-owned clinics and contracted providers. The company operates medical oncology and radiation oncology services on both fee-for-service and value-based contract bases, managing patients under risk-sharing arrangements with payers. Additionally, the company offers specialty pharmacy services and clinical trial management.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Starling Oncology Inc stock.

Our verdict on STLN

Undervalued: intrinsic value $7.16 per share, market price $3.40, margin of safety 52.5% (as of 2026-11-17).

A 1.2x revenue multiple, discounted for its losses, values the shares at $7.16; the price of $3.40 is 53% below that value.

ETFs with the most weight in STLN

17 more funds hold it; the full list is part of the paid plan.

More on STLN

Browse

Peers in Medical Care Facilities

All 48 Medical Care Facilities stocks

Cheaper than STLN in Medical Care Facilities

Is STLN undervalued or overvalued?

STLN is undervalued (as of the 2026-11-17 close). A 1.2x revenue multiple, discounted for its losses, values the shares at $7.16; the price of $3.40 is 53% below that value.

What is the intrinsic value of STLN?

$7.16 per share (as of the 2026-11-17 close), against a market price of $3.40. That is a margin of safety of 52.5%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.